Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.
Martino M et al. Bone Marrow Transplant. 2016 Apr 4. doi: 10.1038/bmt.2016.79. [Epub ahead of print].

Nuances in the Management of Older People With Multiple Myeloma.
Pawlyn C et al. Curr Hematol Malig Rep. 2016 Apr 2. [Epub ahead of print].

Management of multiple myeloma in older adults: Gaining ground with geriatric assessment.
Wildes TM et al. J Geriatr Oncol. 2016 Apr 22. pii: S1879-4068(16)30027-3. doi: 10.1016/j.jgo.2016.04.001. [Epub ahead of print].

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: Trends and outcomes over 25 years. A study by the EBMT CMWP.
Sobh M et al. Leukemia. 2016 Apr 27. doi: 10.1038/leu.2016.101. [Epub ahead of print].

Lack of health maintenance examinations and risk in myeloma patients.
Tariman JD et al. Cancer Med. 2016 Apr 27. doi: 10.1002/cam4.716. [Epub ahead of print].

Increased incidence of bladder cancer, lymphoid leukaemia, and myeloma in a cohort of Queensland melanoma families.
Read J et al. Fam Cancer. 2016 Apr 23. [Epub ahead of print].

Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity.
Costa LJ et al. Leuk Lymphoma. 2016 Apr 22:1-6. [Epub ahead of print].

Histone deacetylase inhibitors in multiple myeloma: from bench to bedside.
Harada T et al. nt J Hematol. 2016 Apr 20. [Epub ahead of print].

Long-term survival consequent on the abscopal effect in a patient with multiple myeloma.
Saba R et al. BMJ Case Rep. 2016 Apr 20;2016. pii: bcr2016215237. doi: 10.1136/bcr-2016-215237.

Bortezomib for the treatment of multiple myeloma.
Scott K et al. Cochrane Database Syst Rev. 2016 Apr 20;4:CD010816. [Epub ahead of print].

Immunotherapy: A New Approach to Treating Multiple Myeloma.
Afifi S et al. Ann Pharmacother. 2016 Apr 15. pii: 1060028016642786. [Epub ahead of print].

Early mortality in multiple myeloma: the time-dependent impact of comorbidity. A population-based study in 621 real-life patients.
Ríos-Tamayo R et al. Am J Hematol. 2016 Apr 13. doi: 10.1002/ajh.24389. [Epub ahead of print].

The Future of Myeloma Therapy: One Size Does Not Fit All.
Richardson PG. J Oncol Pract. 2016 Apr;12(4):295-6. doi: 10.1200/JOP.2016.011502.

Moving Toward a Tailored Therapy in Multiple Myeloma.
D’Agostino M et al. J Oncol Pract. 2016 Apr;12(4):293-4. doi: 10.1200/JOP.2016.011627.

Myeloma Is Not a Single Disease.
Lonial S et al. J Oncol Pract. 2016 Apr;12(4):287-92. doi: 10.1200/JOP.2016.010926.

Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy.
Gonsalves WI et al. Bone Marrow Transplant. 2016 Apr 11. doi: 10.1038/bmt.2016.91. [Epub ahead of print].

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.
Anderson KC et al. J Natl Compr Canc Netw. 2016 Apr;14(4):389-400.

Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma.
Wahaib K et al. Am J Health Syst Pharm. 2016 Apr 1;73(7):441-50. doi: 10.2146/ajhp150487.